Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer

NCT02551263 · clinicaltrials.gov ↗

COMPLETED

Status

201

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Eribulin

Sponsor

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Collaborators

[object Object]